Loading...
Market
How will Bavarian Nordic's stock price react within a week of EU approval of mpox vaccine for adolescents?
2
Resolution / Starting Odds
Increases by more than 10% • 25%
Increases by 5-10% • 25%
Increases by less than 5% • 25%
Decreases or remains the same • 25%
Stock market data from financial news sources like Bloomberg or Reuters
Story
Bavarian Nordic Seeks Critical EU Approval for Mpox Vaccine in Adolescents Aged 12 to 17
Aug 16, 2024, 11:04 AM
Danish biotech company Bavarian Nordic has submitted data to the European Union's drug regulator seeking approval to extend the use of its mpox vaccine to adolescents aged 12 to 17. This move follows the World Health Organization's declaration of a global public health emergency due to a surge in mpox cases. CEO Paul Chaplin emphasized the importance of this approval, describing it as 'critical' for addressing the health crisis.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Approved without conditions • 25%
Approved with conditions • 25%
Not approved • 25%
Decision delayed • 25%
Less than 10 • 25%
10 to 20 • 25%
20 to 30 • 25%
More than 30 • 25%
Less than 30% • 25%
30% to 50% • 25%
50% to 70% • 25%
More than 70% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Stock price increases by 10% or more • 25%
Stock price decreases by 10% or more • 25%
Stock price remains within 10% of current value • 25%
Stock price fluctuates but no clear trend • 25%
Yes • 50%
No • 50%
Less than 1 million • 25%
1 to 3 million • 25%
3 to 5 million • 25%
More than 5 million • 25%